Cidara Therapeutics Inc (CDTX)
13.43
+0.40
(+3.07%)
USD |
NASDAQ |
Nov 05, 16:00
13.43
0.00 (0.00%)
After-Hours: 18:57
Cidara Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 81.53% |
| December 31, 2023 | 93.54% |
| Date | Value |
|---|---|
| September 30, 2023 | 96.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
81.53%
Minimum
Mar 2024
96.96%
Maximum
Sep 2023
90.68%
Average
93.54%
Median
Dec 2023
Gross Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 74.73% |
| Arbutus Biopharma Corp | -- |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 89.78% |
| Cue Biopharma Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -449.1% |
| Return on Assets | -135.8% |
| Return on Invested Capital | -449.1% |
| Profit Margin (Quarterly) | -30.20K% |
| Operating Margin (Quarterly) | -3.68K% |
| Return on Net Operating Assets | -757.8% |